Long-term injections of D-galactose (D-gal) have been widely used to establish AD and aging models because these cause many aging- or AD-like pathological symptoms, such as memory impairments, reduced neurogenesis, increased levels of amyloid precursor protein, and oxidative damage [1, 16, 17]. The gene discussed is APP; the disease is Alzheimer disease.